Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
164M
-
Number of holders
-
72
-
Total 13F shares, excl. options
-
34.5M
-
Shares change
-
-199K
-
Total reported value, excl. options
-
$52M
-
Value change
-
-$652K
-
Put/Call ratio
-
2.44
-
Number of buys
-
20
-
Number of sells
-
-43
-
Price
-
$1.51
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q1 2023
88 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q1 2023.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 72 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.5M shares
of 164M outstanding shares and own 21.01% of the company stock.
Largest 10 shareholders include BVF INC/IL (6.6M shares), TANG CAPITAL MANAGEMENT LLC (6.09M shares), VANGUARD GROUP INC (4.92M shares), ACADIAN ASSET MANAGEMENT LLC (2.65M shares), JACOBS LEVY EQUITY MANAGEMENT, INC (1.89M shares), Laurion Capital Management LP (1.19M shares), MILLENNIUM MANAGEMENT LLC (961K shares), Bronte Capital Management Pty Ltd. (918K shares), RENAISSANCE TECHNOLOGIES LLC (850K shares), and MARSHALL WACE, LLP (730K shares).
This table shows the top 72 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.